ARGENX SE
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.
FY2025 · Filed Mar 19, 2026
Contents
ITEM 16B. CODE OF ETHICS
CODE OF ETHICS
We adopted a Code of Business Conduct and Ethics (Code of Conduct), that is applicable to all of our employees and
directors. Our Code of Conduct translates the core values into a set of clear standards to help guide our conduct as we
navigate the complexities of the highly regulated and competitive global marketplace in which we operate as we work to
become an independent, fully integrated, and global immunology company. Its purpose is not to exhaustively list all the
behaviors we as a company expect from each other. Rather, the Code of Conduct contains key principles for us to live by
as individuals, to ensure that we maximally contribute to argenx’s collective success. [As part of their onboarding, all
employees receive a training on the Code of Conduct and the Directors receive a copy of the Code of Conduct and need
to comply with its terms.] The Code of Conduct is available on our website atwww.argenx. com/investors/governance/
rules-codes-compliance. The Audit and Compliance Committee of our Board of Directors (i) is responsible for
overseeing and evaluating the Code of Conduct and (ii) is required to approve any waivers of the Code of Conduct for
employees and directors. The Audit and Compliance Committee has not received requests for material waivers of the
Code of Conduct in the financial year 2025. We expect that any amendments to the Code of Conduct, and any waivers of
its requirements, will be disclosed on our website.
ITEM 16.C.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.